Antisense Drugs for Rare and Ultra-rare Genetic Neurological Diseases
Overview
Authors
Affiliations
The regulatory approvals of nusinersen and tofersen, plus the large body of clinical and preclinical data from other drugs, have significantly de-risked antisense technology for neurological diseases. The platform learnings over the last 2 decades can be applied to subsequent drugs to improve the efficiency of discovering effective neuro-therapeutics.
Molecular diagnostic approach to rare neurological diseases from a clinician viewpoint.
Lee J Genomics Inform. 2024; 22(1):18.
PMID: 39390516 PMC: 11468364. DOI: 10.1186/s44342-024-00025-0.
Antisense oligonucleotides and their applications in rare neurological diseases.
McDowall S, Aung-Htut M, Wilton S, Li D Front Neurosci. 2024; 18:1414658.
PMID: 39376536 PMC: 11456401. DOI: 10.3389/fnins.2024.1414658.
Therapeutic targeting of RNA for neurological and neuromuscular disease.
Bubenik J, Scotti M, Swanson M Genes Dev. 2024; 38(15-16):698-717.
PMID: 39142832 PMC: 11444190. DOI: 10.1101/gad.351612.124.
Ube3a unsilencer for the potential treatment of Angelman syndrome.
Vihma H, Li K, Welton-Arndt A, Smith A, Bettadapur K, Gilmore R Nat Commun. 2024; 15(1):5558.
PMID: 38977672 PMC: 11231141. DOI: 10.1038/s41467-024-49788-8.
Targeting RNA opens therapeutic avenues for Timothy syndrome.
Velasco S Nature. 2024; 628(8009):730-732.
PMID: 38600188 DOI: 10.1038/d41586-024-00911-1.